C-Telopeptide Normal Range and What Your Levels Mean

C-telopeptide (CTX) is a fragment of type I collagen released into the bloodstream when bone is broken down, and its normal range depends heavily on your age, sex, and menopausal status. In premenopausal women, typical values run roughly 100–700 ng/L, while men in midlife generally fall between 130–600 ng/L. But those numbers shift across the lifespan, and a single result without context can be misleading. CTX is one of the two bone turnover markers that international osteoporosis organizations have endorsed as a reference standard, and understanding what your level actually means requires knowing not just the number, but when and how your blood was drawn, what medications you take, and what your doctor is looking for.

What CTX Actually Measures

Your skeleton is not a static structure. It constantly remodels itself: specialized cells called osteoclasts dissolve old bone, and osteoblasts lay down new bone in its place. CTX is a byproduct of the demolition side of that cycle. When osteoclasts chew through bone matrix, they break apart type I collagen, and small fragments from the C-terminal end of those collagen molecules spill into your blood.¹ A higher CTX level means more bone is being broken down; a lower level means less.

In 2011, the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) designated two markers as the standard references for bone turnover in osteoporosis research and clinical care: CTX for bone resorption and P1NP for bone formation.² That pairing gives clinicians a snapshot of both sides of the remodeling cycle. CTX tells them how fast bone is being lost; P1NP tells them how fast new bone is being built.

Normal Ranges by Age and Sex

Reference intervals for CTX are not one-size-fits-all. A study that established age-stratified ranges from an Australian reference population broke them down this way for men: ages 25–40, 170–600 ng/L; ages 40–60, 130–600 ng/L; and over 60, 100–600 ng/L. For women: under 30, 150–800 ng/L; 30–39, 100–700 ng/L; 40–49, 100–600 ng/L; and 50 and older, 100–700 ng/L.³ The wider upper range in postmenopausal women reflects the uptick in bone breakdown that occurs after estrogen levels drop.

A large Chinese study of over 1,400 subjects found a broadly similar pattern. CTX peaked in both sexes between ages 15 and 19, then gradually declined through adulthood. In women, levels rose again around menopause and stayed elevated until the mid-60s before declining once more. In men, levels stayed relatively low from around age 40 onward and drifted lower still after 70.⁴ The premenopausal median in that study was 0.26 ng/mL (equivalent to 260 ng/L), which sits comfortably within the Australian intervals.

Young adults under 25 often register CTX values that would look alarmingly high if compared against midlife reference ranges. That is because their skeletons are still growing and consolidating bone mass, and high turnover is a normal part of that process.³ If you are in your late teens or early twenties and your doctor ordered CTX, keep that context in mind.

Why Fasting and Timing Matter So Much

CTX is unusually sensitive to when you ate and when the blood was drawn. Eating a meal can drop serum CTX by about 18% compared to the fasting level, a bigger swing than for almost any other bone marker.⁵ A separate study confirmed that consuming breakfast reduced CTX for one to four hours afterward.⁶ That is why the National Bone Health Alliance recommends collecting CTX samples consistently in the morning after an overnight fast.⁷

On top of the food effect, CTX has a strong circadian rhythm. In humans, it peaks around 5 a.m. and hits its lowest point around 2 p.m., swinging roughly 40% above and below the 24-hour mean.⁸ That rhythm persists regardless of menopausal status, bed rest, or even blindness, so it is driven by an internal clock rather than by activity or light exposure. The practical upshot: a sample drawn at 8 a.m. fasting will not be comparable to one drawn at 3 p.m. after lunch. If your levels are being tracked over time, the draws need to happen under the same conditions each time or the comparison is meaningless.

What Elevated CTX Can Mean

A CTX value above the reference range signals that bone resorption is running faster than expected. The most common reason in clinical practice is postmenopausal osteoporosis. After menopause, estrogen withdrawal accelerates osteoclast activity, and CTX rises accordingly. But high CTX is not unique to osteoporosis. Several other conditions can drive it up.

Paget’s disease of bone is one striking example. In active Paget’s, the abnormal bone that forms is woven rather than the orderly lamellar type, and the ratio between two forms of CTX fragments shifts dramatically. The non-isomerized (alpha) form of CTX is overrepresented relative to the beta-isomerized form, reaching roughly three times the normal ratio.⁹ That alpha-to-beta imbalance normalizes after bisphosphonate treatment, probably because the newly formed bone at treated sites is structurally normal.¹⁰

Hyperthyroidism and hyperparathyroidism also raise CTX, because excess thyroid hormone and parathyroid hormone both accelerate bone turnover. Severe vitamin D deficiency can push up parathyroid hormone as a secondary effect, and in people whose parathyroid hormone was elevated at baseline, correcting the vitamin D deficiency with supplements brought CTX down, though only when calcium was also supplemented.¹¹ Vitamin D alone was not enough to lower CTX.¹²

Glucocorticoids, commonly prescribed for conditions like rheumatoid arthritis and COPD, affect CTX in a pattern that can be confusing. In the short term, corticosteroids tend to suppress CTX, so the number drops. A randomized study of prednisolone in early rheumatoid arthritis found that CTX fell significantly in the steroid-treated group.¹³ A trial in COPD patients showed a 24% drop in CTX at three months with a standard corticosteroid course.¹⁴ But this does not mean steroids are protecting bone. They simultaneously suppress bone formation even more aggressively, and the net result over months to years is bone loss. A temporarily low CTX during corticosteroid use can be falsely reassuring.

What Low CTX Can Mean

A very low CTX reading usually means bone resorption has been suppressed. The most common reason is treatment with anti-resorptive drugs like bisphosphonates (alendronate, risedronate, zoledronate) or denosumab. These medications work by slowing osteoclast activity, and a drop in CTX is exactly what clinicians look for to confirm the drug is working.

Outside of treatment, persistently low CTX in someone not on medication is less common and generally less worrisome than a high value, though extremely low turnover in certain clinical contexts has raised questions about whether bone repair mechanisms might be impaired. The relationship between declining bone turnover markers and bone density was illustrated in a study of postmenopausal women, which found that decreases in CTX correlated with short-term improvements in lumbar spine bone mineral density.¹⁵ That same study identified physical activity and drug treatment as the strongest predictors of favorable changes in bone density.

Using CTX to Monitor Osteoporosis Treatment

One of the main clinical uses of CTX is checking whether oral bisphosphonate therapy is actually being taken consistently and working. Many patients skip doses or stop taking their medication without telling their doctor, and a bone density scan takes a year or two to show a meaningful change. CTX, by contrast, can shift within weeks.

A 2025 consensus statement from ESCEO, the IOF, and the IFCC reaffirmed that CTX and P1NP are the recommended reference markers for monitoring osteoporosis treatment.¹⁶ An algorithm-based review recommended that suppression of CTX to the lower half of the premenopausal reference range, or a drop exceeding the “least significant change” threshold, is a reliable sign of adherence and treatment response.¹⁷ A newer study proposed an “expected change” concept to refine this further, arguing that monitoring should use biological endpoints rather than purely statistical ones.¹⁸

For patients coming off denosumab, CTX monitoring matters for a different reason: rebound. Denosumab suppresses bone resorption powerfully, but the effect wears off after the injection interval. A real-world study found that after discontinuing denosumab and receiving a zoledronate infusion as a bridging therapy, CTX rose in a nonlinear pattern, peaking at six to nine months and reaching a partial plateau by a year. The peak values stayed below the upper reference limit for premenopausal women, suggesting the rebound was contained.¹⁹ Without a bridging drug, the rebound can be much more severe, which is why clinicians track CTX closely during these transitions.

Kidney Function and CTX Accuracy

If you have chronic kidney disease, your CTX results may be misleading. CTX fragments are cleared through the kidneys, so as kidney function declines, CTX accumulates in the blood regardless of what the skeleton is doing. A study of CTX circadian rhythms in kidney disease patients confirmed that their overall CTX levels were higher than expected, and concluded that no validated reference ranges exist for people with reduced kidney function. The authors went so far as to say CTX is inappropriate for treatment monitoring in that population.²⁰ If your kidney function is significantly impaired, your doctor may lean more heavily on other markers or on bone density imaging instead.

Fractures and Healing

A recent fracture will temporarily spike your CTX. A study tracking patients after surgical fixation of tibia and femur fractures found that serum CTX jumped about 64% above baseline at six weeks and was still about 32% elevated at twelve weeks.²¹ This makes sense: healing bone requires old, damaged tissue to be cleared away before new bone fills the gap. If you recently broke a bone and your CTX looks high, it may simply reflect active repair rather than a disease process.

Exercise, Cycling, and Acute Changes

Physical activity has a more nuanced relationship with CTX than you might expect. A systematic review and meta-analysis of exercise studies found that cycling, specifically, produced a moderate increase in CTX, with the peak response occurring within two hours after the bout. Longer and harder cycling sessions produced bigger spikes. Other exercise types, including impact-loading activities, did not meaningfully alter CTX.²² A separate study looking at a single session of jumping exercise found no significant change in CTX over a 24-hour period compared to a rest day.²³

The cycling finding is interesting because it suggests that prolonged non-weight-bearing endurance exercise may transiently accelerate bone resorption in a way that impact exercise does not. For recreational exercisers, this is not something to worry about. For elite cyclists or triathletes whose bone density is already a concern, it is one more data point worth discussing with a sports medicine physician.

CTX in Children and Adolescents

Pediatric CTX values look nothing like adult values, and applying adult reference ranges to a child’s result would be a mistake. A systematic review pooling data from multiple studies found that CTX stays relatively constant during pre-pubertal years, then spikes dramatically during puberty as the skeleton grows rapidly, before plummeting toward adult levels.²⁴ A Danish study of children and adolescents found that CTX and P1NP were the markers most affected by growth-related changes, with boys showing a particularly steep initial rise and girls showing a more pronounced post-pubertal decline.²⁵ Pediatric endocrinologists use age- and sex-specific reference intervals rather than adult cutoffs for exactly this reason.

Serum Versus Urine Testing

You might encounter both serum (blood) and urine CTX results, and it helps to know the difference. Historically, urine-based collagen fragments were the first resorption markers available, but serum testing has become the preferred method. A comparison study found that serum and urine CTX correlated reasonably well and reflected menopause-associated increases in bone resorption with similar sensitivity.²⁶ Another study concluded that serum markers reflect bone resorption to the same degree as urinary ones while sidestepping some of the practical limitations of urine collection, like the need to correct for creatinine and deal with variable hydration.²⁷ That is why most guidelines now specify serum CTX as the standard.

Why Your Number May Not Match the Lab’s Printed Range

One frustrating wrinkle is that different laboratories use different CTX assays, and results from one platform are not always directly comparable to another. A multicenter study evaluating harmonization across CTX assay methods found significant variation between methods and between testing centers, though plasma samples tended to produce more consistent results than serum samples across platforms.²⁸ Efforts to standardize CTX measurement are ongoing, but for now, you should always compare your result against the specific reference range printed by the lab that ran your test, not against numbers you found online or from a different lab’s report. And if your doctor is tracking CTX over time, ideally the samples should be run on the same assay platform each time.

This assay variability also explains why you may see slightly different “normal” ranges quoted in different sources. The Australian reference intervals, the Chinese reference intervals, and whatever your local lab uses may not align perfectly. The patterns are consistent (lowest in midlife, higher around menopause, highest during adolescent growth), but the exact cutoffs depend on the population studied and the instrument used. A recent proposal to establish common reference intervals for CTX across assay platforms is still working its way through the literature.²⁹ Until that standardization is achieved, the specific numbers on your lab report deserve more trust than any generic range.